,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2010', 'fs': 'Oct 2010', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSnYE2A1'}, 'Id': 'a0POZ00000FSnYE2A1', 'Event_Date__c': '2010-10-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Oct 2010', 'Status_History__c': 'a132P000000ApfNQAS'}, 'change': None}]",Oct 2010,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-02.pdf "" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-02.pdf "" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2011', 'fs': 'Feb 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2011.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2011.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSnYH2A1'}, 'Id': 'a0POZ00000FSnYH2A1', 'Event_Date__c': '2011-02-17', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2011.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-02.pdf "" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Feb 2011', 'Status_History__c': 'a132P000000ApmqQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2022', 'fs': 'Oct 2022', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 17 November 2022', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 17 November 2022', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSnYL2A1'}, 'Id': 'a0POZ00000FSnYL2A1', 'Event_Date__c': '2022-10-21', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 17 November 2022', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Oct 2022', 'Status_History__c': 'a132P000000E85dQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""font-size: 14px; color: black;"">1.1.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px; color: rgb(68, 68, 68);"">The Committee </span><strong style=""font-size: 14px; color: rgb(68, 68, 68);"">recommended</strong><span style=""font-size: 14px; color: rgb(68, 68, 68);""> that the application for clodronate for the treatment of osteoradionecrosis be </span><strong style=""font-size: 14px; color: rgb(68, 68, 68);"">declined</strong><span style=""font-size: 14px; color: rgb(68, 68, 68);"">.\xa0</span></p>', 'fs': '<p><span style=""font-size: 14px; color: black;"">1.1.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px; color: rgb(68, 68, 68);"">The Committee </span><strong style=""font-size: 14px; color: rgb(68, 68, 68);"">recommended</strong><span style=""font-size: 14px; color: rgb(68, 68, 68);""> that the application for clodronate for the treatment of osteoradionecrosis be </span><strong style=""font-size: 14px; color: rgb(68, 68, 68);"">declined</strong><span style=""font-size: 14px; color: rgb(68, 68, 68);"">.\xa0</span></p>', 'change': None}, 'Published_Discussion': {'s': '<h2><strong>Background</strong></h2><p><span style=""font-size: 14px; color: black;"">1.1.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that a clinician application for clodronate for the treatment of osteoradionecrosis was recommended for decline by PTAC in </span><a href=""https://pharmac.govt.nz/assets/ptac-minutes-2011-02.pdf"" target=""_blank"" style=""font-size: 14px;"">February 2011</a><span style=""font-size: 14px;"">. At the time, the Committee considered that the evidence supporting the use of clodronate as a treatment for osteoradionecrosis was weak with only two non-experimental cohort studies available, and that there was no evidence of health benefit from clodronate provided by the applicant or in any other literature it reviewed.</span></p><p><span style=""font-size: 14px; color: black;"">1.2.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that in 2019, Pharmac publicly </span><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-funding-applications/"" target=""_blank"" style=""font-size: 14px;"">consulted on declining</a><span style=""font-size: 14px;""> a number of funding applications, including clodronate for osteoradionecrosis. The Committee noted that one reply was received regarding the use and efficacy of PENtoxifylline+TOcopherol+CLOdronate (ie PENTOCLO protocol) in treatment of osteoradionecrosis. The Committee noted that pentoxifylline and tocopherol are already available without restriction, and that the PENTO protocol utilising these drugs is also used in the treatment of osteoradionecrosis. </span></p><h2><strong>Discussion</strong></h2><p><span style=""font-size: 14px; color: black;"">1.3.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that osteoradionecrosis occurs when irradiated bone becomes devitalised and exposed through the overlaying skin or mucosa without healing for three months or more, and that this typically occurs in the mandible. The Committee noted that the majority of cases occur within the first three years of radiotherapy, and that radiotherapy in combination with chemotherapy may increase the risk of developing osteoradionecrosis even further. The Committee noted that other risk factors include poor oral hygiene, and tobacco and alcohol use. </span></p><p><span style=""font-size: 14px; color: black;"">1.4.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that conservative management of osteoradionecrosis can involve antibiotic treatment, improvement in oral hygiene, and medical management with pentoxifylline and tocopherol. The Committee noted that hyperbaric oxygen treatment has also occasionally been used in the treatment of osteoradionecrosis and considered that this treatment is ineffective. The Committee also noted that surgical treatment is an option for individuals who have more severe osteoradionecrosis, or for whom conservative management was ineffective or inappropriate.\xa0</span></p><p><span style=""font-size: 14px; color: black;"">1.5.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that pentoxifylline is suggested to improve blood flow and vascularisation, tocopherol is an anti-oxidant vitamin-E analogue, and that clodronate is a bisphosphate added to promote osteoblast differentiation and osteogenesis (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30981534/"" target=""_blank"" style=""font-size: 14px;"">Breik et al. Int J Oral Maxillofac Surg. 2019;48:1022-7</a><span style=""font-size: 14px;"">). </span></p><p><span style=""font-size: 14px; color: black;"">1.6.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted the following evidence relating to the use of clodronate in the PENTOCLO regimen for the treatment of osteoradionecrosis: </span></p><p class=""ql-indent-1""><span style=""font-size: 14px;"">1.6.1.</span><span style=""font-size: 14px;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30205911/"" target=""_blank"" style=""font-size: 14px;"">Kolokythas et al. Int J Oral Maxillofac Surg. 2019;48:173-80</a><span style=""font-size: 14px;"">: a meta-analysis including seven studies on the use of pentoxifylline and tocopherol with or without clodronate for the treatment of osteoradionecrosis which reported that the current literature supports the use of clodronate in this setting. </span></p><p class=""ql-indent-1""><span style=""font-size: 14px;"">1.6.2.</span><span style=""font-size: 14px;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/15641107/"" target=""_blank"" style=""font-size: 14px;"">Delanian et al. Head Neck. 2005;27:114-23</a><span style=""font-size: 14px;"">: a cohort study in which 18 patients were treated with the PENTO combination, with the eight most severe patients being treated with PENTOCLO. The Committee noted that all patients improved but considered it unclear if clodronate provided any additional benefit over the PENTO combination regimen. </span></p><p class=""ql-indent-1""><span style=""font-size: 14px;"">1.6.3.</span><span style=""font-size: 14px;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33385466/"" target=""_blank"" style=""font-size: 14px;"">Patel et al. Radiother Oncol. 2021;156:209-16</a><span style=""font-size: 14px;"">: a retrospective study of patients with osteoradionecrosis treated with either PENTO or PENTOCLO which reported that 54.4% of patients had healed after 12.9 months, and that PENTO was significantly superior to PENTOCLO. </span></p><p class=""ql-indent-1""><span style=""font-size: 14px;"">1.6.4.</span><span style=""font-size: 14px;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31747060/"" target=""_blank"" style=""font-size: 14px;"">Dissard et al. Laryngoscope. 2020;130:E559-66</a><span style=""font-size: 14px;"">: a prospective cohort study of patients with mandibular osteoradionecrosis treated with PENTOCLO which reported that exposed bone area decreased by 92% at 24 months. </span></p><p><span style=""font-size: 14px; color: black;"">1.7.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee considered that the above evidence was of low strength and quality. </span></p><p><span style=""font-size: 14px; font-family: Arial, sans-serif;"">Committee noted that while there have been no randomised controlled trials of clodronate for osteoradionecrosis to date, the</span><a href=""https://fundingawards.nihr.ac.uk/award/NIHR131050"" target=""_blank"" style=""font-size: 14px; font-family: Arial, sans-serif;""> RAPTOR trial</a><span style=""font-size: 14px; font-family: Arial, sans-serif;""> (an unblinded, randomised, controlled trial) which aims to compare standard supportive care (SSC) against SSC plus PENTOCLO, measuring time-to-healing as primary endpoint, is currently being conducted. The Committee therefore considered that a funding recommendation for clodronate in this indication should be declined pending further review subsequent to a funding application following publication of trial results for the RAPTOR trial, which are expected in 2026, and/or if any other relevant evidence becomes available</span></p>', 'fs': '<h2><strong>Background</strong></h2><p><span style=""font-size: 14px; color: black;"">1.1.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that a clinician application for clodronate for the treatment of osteoradionecrosis was recommended for decline by PTAC in </span><a href=""https://pharmac.govt.nz/assets/ptac-minutes-2011-02.pdf"" target=""_blank"" style=""font-size: 14px;"">February 2011</a><span style=""font-size: 14px;"">. At the time, the Committee considered that the evidence supporting the use of clodronate as a treatment for osteoradionecrosis was weak with only two non-experimental cohort studies available, and that there was no evidence of health benefit from clodronate provided by the applicant or in any other literature it reviewed.</span></p><p><span style=""font-size: 14px; color: black;"">1.2.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that in 2019, Pharmac publicly </span><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-funding-applications/"" target=""_blank"" style=""font-size: 14px;"">consulted on declining</a><span style=""font-size: 14px;""> a number of funding applications, including clodronate for osteoradionecrosis. The Committee noted that one reply was received regarding the use and efficacy of PENtoxifylline+TOcopherol+CLOdronate (ie PENTOCLO protocol) in treatment of osteoradionecrosis. The Committee noted that pentoxifylline and tocopherol are already available without restriction, and that the PENTO protocol utilising these drugs is also used in the treatment of osteoradionecrosis. </span></p><h2><strong>Discussion</strong></h2><p><span style=""font-size: 14px; color: black;"">1.3.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that osteoradionecrosis occurs when irradiated bone becomes devitalised and exposed through the overlaying skin or mucosa without healing for three months or more, and that this typically occurs in the mandible. The Committee noted that the majority of cases occur within the first three years of radiotherapy, and that radiotherapy in combination with chemotherapy may increase the risk of developing osteoradionecrosis even further. The Committee noted that other risk factors include poor oral hygiene, and tobacco and alcohol use. </span></p><p><span style=""font-size: 14px; color: black;"">1.4.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that conservative management of osteoradionecrosis can involve antibiotic treatment, improvement in oral hygiene, and medical management with pentoxifylline and tocopherol. The Committee noted that hyperbaric oxygen treatment has also occasionally been used in the treatment of osteoradionecrosis and considered that this treatment is ineffective. The Committee also noted that surgical treatment is an option for individuals who have more severe osteoradionecrosis, or for whom conservative management was ineffective or inappropriate.\xa0</span></p><p><span style=""font-size: 14px; color: black;"">1.5.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that pentoxifylline is suggested to improve blood flow and vascularisation, tocopherol is an anti-oxidant vitamin-E analogue, and that clodronate is a bisphosphate added to promote osteoblast differentiation and osteogenesis (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30981534/"" target=""_blank"" style=""font-size: 14px;"">Breik et al. Int J Oral Maxillofac Surg. 2019;48:1022-7</a><span style=""font-size: 14px;"">). </span></p><p><span style=""font-size: 14px; color: black;"">1.6.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted the following evidence relating to the use of clodronate in the PENTOCLO regimen for the treatment of osteoradionecrosis: </span></p><p class=""ql-indent-1""><span style=""font-size: 14px;"">1.6.1.</span><span style=""font-size: 14px;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30205911/"" target=""_blank"" style=""font-size: 14px;"">Kolokythas et al. Int J Oral Maxillofac Surg. 2019;48:173-80</a><span style=""font-size: 14px;"">: a meta-analysis including seven studies on the use of pentoxifylline and tocopherol with or without clodronate for the treatment of osteoradionecrosis which reported that the current literature supports the use of clodronate in this setting. </span></p><p class=""ql-indent-1""><span style=""font-size: 14px;"">1.6.2.</span><span style=""font-size: 14px;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/15641107/"" target=""_blank"" style=""font-size: 14px;"">Delanian et al. Head Neck. 2005;27:114-23</a><span style=""font-size: 14px;"">: a cohort study in which 18 patients were treated with the PENTO combination, with the eight most severe patients being treated with PENTOCLO. The Committee noted that all patients improved but considered it unclear if clodronate provided any additional benefit over the PENTO combination regimen. </span></p><p class=""ql-indent-1""><span style=""font-size: 14px;"">1.6.3.</span><span style=""font-size: 14px;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33385466/"" target=""_blank"" style=""font-size: 14px;"">Patel et al. Radiother Oncol. 2021;156:209-16</a><span style=""font-size: 14px;"">: a retrospective study of patients with osteoradionecrosis treated with either PENTO or PENTOCLO which reported that 54.4% of patients had healed after 12.9 months, and that PENTO was significantly superior to PENTOCLO. </span></p><p class=""ql-indent-1""><span style=""font-size: 14px;"">1.6.4.</span><span style=""font-size: 14px;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31747060/"" target=""_blank"" style=""font-size: 14px;"">Dissard et al. Laryngoscope. 2020;130:E559-66</a><span style=""font-size: 14px;"">: a prospective cohort study of patients with mandibular osteoradionecrosis treated with PENTOCLO which reported that exposed bone area decreased by 92% at 24 months. </span></p><p><span style=""font-size: 14px; color: black;"">1.7.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee considered that the above evidence was of low strength and quality. </span></p><p><span style=""font-size: 14px; font-family: Arial, sans-serif;"">Committee noted that while there have been no randomised controlled trials of clodronate for osteoradionecrosis to date, the</span><a href=""https://fundingawards.nihr.ac.uk/award/NIHR131050"" target=""_blank"" style=""font-size: 14px; font-family: Arial, sans-serif;""> RAPTOR trial</a><span style=""font-size: 14px; font-family: Arial, sans-serif;""> (an unblinded, randomised, controlled trial) which aims to compare standard supportive care (SSC) against SSC plus PENTOCLO, measuring time-to-healing as primary endpoint, is currently being conducted. The Committee therefore considered that a funding recommendation for clodronate in this indication should be declined pending further review subsequent to a funding application following publication of trial results for the RAPTOR trial, which are expected in 2026, and/or if any other relevant evidence becomes available</span></p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""font-size: 14px; color: black;"">1.1.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee reviewed the feedback relating to the consultation to decline the application for clodronate for osteoradionecrosis.\xa0</span></p><p><span style=""font-size: 14px; color: black;"">1.2.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</span></p>', 'fs': '<p><span style=""font-size: 14px; color: black;"">1.1.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee reviewed the feedback relating to the consultation to decline the application for clodronate for osteoradionecrosis.\xa0</span></p><p><span style=""font-size: 14px; color: black;"">1.2.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</span></p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2023', 'fs': 'Mar 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 November 2022.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 November 2022.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSnYM2A1'}, 'Id': 'a0POZ00000FSnYM2A1', 'Event_Date__c': '2023-03-20', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 November 2022.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Mar 2023', 'Published_Recommendation__c': '<p><span style=""font-size: 14px; color: black;"">1.1.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px; color: rgb(68, 68, 68);"">The Committee </span><strong style=""font-size: 14px; color: rgb(68, 68, 68);"">recommended</strong><span style=""font-size: 14px; color: rgb(68, 68, 68);""> that the application for clodronate for the treatment of osteoradionecrosis be </span><strong style=""font-size: 14px; color: rgb(68, 68, 68);"">declined</strong><span style=""font-size: 14px; color: rgb(68, 68, 68);"">.\xa0</span></p>', 'Published_Application__c': '<p><span style=""font-size: 14px; color: black;"">1.1.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee reviewed the feedback relating to the consultation to decline the application for clodronate for osteoradionecrosis.\xa0</span></p><p><span style=""font-size: 14px; color: black;"">1.2.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</span></p>', 'Published_Discussion__c': '<h2><strong>Background</strong></h2><p><span style=""font-size: 14px; color: black;"">1.1.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that a clinician application for clodronate for the treatment of osteoradionecrosis was recommended for decline by PTAC in </span><a href=""https://pharmac.govt.nz/assets/ptac-minutes-2011-02.pdf"" target=""_blank"" style=""font-size: 14px;"">February 2011</a><span style=""font-size: 14px;"">. At the time, the Committee considered that the evidence supporting the use of clodronate as a treatment for osteoradionecrosis was weak with only two non-experimental cohort studies available, and that there was no evidence of health benefit from clodronate provided by the applicant or in any other literature it reviewed.</span></p><p><span style=""font-size: 14px; color: black;"">1.2.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that in 2019, Pharmac publicly </span><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-funding-applications/"" target=""_blank"" style=""font-size: 14px;"">consulted on declining</a><span style=""font-size: 14px;""> a number of funding applications, including clodronate for osteoradionecrosis. The Committee noted that one reply was received regarding the use and efficacy of PENtoxifylline+TOcopherol+CLOdronate (ie PENTOCLO protocol) in treatment of osteoradionecrosis. The Committee noted that pentoxifylline and tocopherol are already available without restriction, and that the PENTO protocol utilising these drugs is also used in the treatment of osteoradionecrosis. </span></p><h2><strong>Discussion</strong></h2><p><span style=""font-size: 14px; color: black;"">1.3.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that osteoradionecrosis occurs when irradiated bone becomes devitalised and exposed through the overlaying skin or mucosa without healing for three months or more, and that this typically occurs in the mandible. The Committee noted that the majority of cases occur within the first three years of radiotherapy, and that radiotherapy in combination with chemotherapy may increase the risk of developing osteoradionecrosis even further. The Committee noted that other risk factors include poor oral hygiene, and tobacco and alcohol use. </span></p><p><span style=""font-size: 14px; color: black;"">1.4.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that conservative management of osteoradionecrosis can involve antibiotic treatment, improvement in oral hygiene, and medical management with pentoxifylline and tocopherol. The Committee noted that hyperbaric oxygen treatment has also occasionally been used in the treatment of osteoradionecrosis and considered that this treatment is ineffective. The Committee also noted that surgical treatment is an option for individuals who have more severe osteoradionecrosis, or for whom conservative management was ineffective or inappropriate.\xa0</span></p><p><span style=""font-size: 14px; color: black;"">1.5.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted that pentoxifylline is suggested to improve blood flow and vascularisation, tocopherol is an anti-oxidant vitamin-E analogue, and that clodronate is a bisphosphate added to promote osteoblast differentiation and osteogenesis (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30981534/"" target=""_blank"" style=""font-size: 14px;"">Breik et al. Int J Oral Maxillofac Surg. 2019;48:1022-7</a><span style=""font-size: 14px;"">). </span></p><p><span style=""font-size: 14px; color: black;"">1.6.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee noted the following evidence relating to the use of clodronate in the PENTOCLO regimen for the treatment of osteoradionecrosis: </span></p><p class=""ql-indent-1""><span style=""font-size: 14px;"">1.6.1.</span><span style=""font-size: 14px;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30205911/"" target=""_blank"" style=""font-size: 14px;"">Kolokythas et al. Int J Oral Maxillofac Surg. 2019;48:173-80</a><span style=""font-size: 14px;"">: a meta-analysis including seven studies on the use of pentoxifylline and tocopherol with or without clodronate for the treatment of osteoradionecrosis which reported that the current literature supports the use of clodronate in this setting. </span></p><p class=""ql-indent-1""><span style=""font-size: 14px;"">1.6.2.</span><span style=""font-size: 14px;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/15641107/"" target=""_blank"" style=""font-size: 14px;"">Delanian et al. Head Neck. 2005;27:114-23</a><span style=""font-size: 14px;"">: a cohort study in which 18 patients were treated with the PENTO combination, with the eight most severe patients being treated with PENTOCLO. The Committee noted that all patients improved but considered it unclear if clodronate provided any additional benefit over the PENTO combination regimen. </span></p><p class=""ql-indent-1""><span style=""font-size: 14px;"">1.6.3.</span><span style=""font-size: 14px;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33385466/"" target=""_blank"" style=""font-size: 14px;"">Patel et al. Radiother Oncol. 2021;156:209-16</a><span style=""font-size: 14px;"">: a retrospective study of patients with osteoradionecrosis treated with either PENTO or PENTOCLO which reported that 54.4% of patients had healed after 12.9 months, and that PENTO was significantly superior to PENTOCLO. </span></p><p class=""ql-indent-1""><span style=""font-size: 14px;"">1.6.4.</span><span style=""font-size: 14px;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31747060/"" target=""_blank"" style=""font-size: 14px;"">Dissard et al. Laryngoscope. 2020;130:E559-66</a><span style=""font-size: 14px;"">: a prospective cohort study of patients with mandibular osteoradionecrosis treated with PENTOCLO which reported that exposed bone area decreased by 92% at 24 months. </span></p><p><span style=""font-size: 14px; color: black;"">1.7.</span><span style=""font-size: 14px; color: black;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 14px;"">The Committee considered that the above evidence was of low strength and quality. </span></p><p><span style=""font-size: 14px; font-family: Arial, sans-serif;"">Committee noted that while there have been no randomised controlled trials of clodronate for osteoradionecrosis to date, the</span><a href=""https://fundingawards.nihr.ac.uk/award/NIHR131050"" target=""_blank"" style=""font-size: 14px; font-family: Arial, sans-serif;""> RAPTOR trial</a><span style=""font-size: 14px; font-family: Arial, sans-serif;""> (an unblinded, randomised, controlled trial) which aims to compare standard supportive care (SSC) against SSC plus PENTOCLO, measuring time-to-healing as primary endpoint, is currently being conducted. The Committee therefore considered that a funding recommendation for clodronate in this indication should be declined pending further review subsequent to a funding application following publication of trial results for the RAPTOR trial, which are expected in 2026, and/or if any other relevant evidence becomes available</span></p>', 'Status_History__c': 'a132P000000EDjUQAW'}, 'change': None}]",Feb 2011,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2011', 'fs': 'Feb 2011', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSnYF2A1'}, 'Id': 'a0POZ00000FSnYF2A1', 'Event_Date__c': '2011-02-01', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2011', 'Status_History__c': 'a132P000000BEeqQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSnYN2A1'}, 'Id': 'a0POZ00000FSnYN2A1', 'Event_Date__c': '2023-07-19', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a13OZ000000tcslYAA'}, 'change': None}]",Feb 2011,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2011', 'fs': 'Feb 2011', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSnYG2A1'}, 'Id': 'a0POZ00000FSnYG2A1', 'Event_Date__c': '2011-02-14', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Feb 2011', 'Status_History__c': 'a132P000000ApmiQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2018', 'fs': 'Dec 2018', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSnYI2A1'}, 'Id': 'a0POZ00000FSnYI2A1', 'Event_Date__c': '2018-12-04', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2018', 'Status_History__c': 'a132P000000ArZrQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2023', 'fs': 'Sep 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSnYO2A1'}, 'Id': 'a0POZ00000FSnYO2A1', 'Event_Date__c': '2023-09-08', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2023', 'Status_History__c': 'a13OZ000001vnvUYAQ'}, 'change': None}]",Feb 2011,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p>The consultation can be found here:</p><p><a href=""https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/"" target=""_blank"">https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/</a></p>', 'fs': '<p>The consultation can be found here:</p><p><a href=""https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/"" target=""_blank"">https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2019', 'fs': 'Dec 2019', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSnYJ2A1'}, 'Id': 'a0POZ00000FSnYJ2A1', 'Event_Date__c': '2019-12-17', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p>The consultation can be found here:</p><p><a href=""https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/"" target=""_blank"">https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/</a></p>', 'Formatted_Date__c': 'Dec 2019', 'Status_History__c': 'a132P000000BeS3QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2024', 'fs': 'Oct 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSnYP2A1'}, 'Id': 'a0POZ00000FSnYP2A1', 'Event_Date__c': '2024-10-17', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'Formatted_Date__c': 'Oct 2024', 'Status_History__c': 'a13OZ00000FTs4QYAT'}, 'change': None}]",Dec 2019,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2020', 'fs': 'Jan 2020', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSnYK2A1'}, 'Id': 'a0POZ00000FSnYK2A1', 'Event_Date__c': '2020-01-31', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Jan 2020', 'Status_History__c': 'a132P000000BeS8QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2024', 'fs': 'Nov 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSnYQ2A1'}, 'Id': 'a0POZ00000FSnYQ2A1', 'Event_Date__c': '2024-11-30', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Nov 2024', 'Status_History__c': 'a13OZ00000HCqUSYA1'}, 'change': None}]",Jan 2020,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
